Additionally, in HCC, Lou et al. indicated that MSCs Exos promoted miR-122-enhanced HCC cell chemosensitivity to sorafenib in HCC cells by downregulating the expression of miR-122 target genes, such as cyclin G1 (CCNG1), disintegrin and metalloprotease 10 (ADAM10), and insulin-like growth factor receptor 1 (IGF1R), which are involved in the drug sensitivity or resistance of cancer cells. The gene discussed is CCNG1; the disease is cancer.